Toggle Health Problems and D

Those taking Ivermectin for COVID were 3X less likely to die (1,000 people, 18 months) – March 2022

One person said this paper was retracted, but it appears to be there March 11

Treatment with Ivermectin Is Associated with Decreased Mortality in COVID-19 Patients: Analysis of a National Federated Database

International Journal of Infectious Diseases. https://doi.org/10.1016/j.ijid.2021.12.096
Efimenko1S.Nackeeran2S.Jabori3J.A. GonzalezZamora4S.Danker3D.Singh1

To evaluate the difference in mortality of patients treated with ivermectin vs patients treated with remdesivir with COVID-19 in United States using TriNetX Research network, a federated EMR network of over 44 healthcare organizations and 68 million patients from US, from 2009-2021.

Methods & Materials
We retrospectively identified adults (≥18 years) with a recorded COVID-19 infection between January 1, 2020 and July 11, 2021. We compared those with recorded use of ivermectin, but not remdesivir, against those with recorded use of remdesivir, but not ivermectin. We controlled for the following demographics, comorbidities, and treatments that may affect COVID-19 survival outcomes: age, gender, race, ethnicity, nicotine use diabetes mellitus, obesity, chronic lower respiratory disease, ischemic heart diseases, tocilizumab, glucocorticoids, or ventilator use. We measured association with mortality as the primary outcome, with significance assessed at p<0.05.

There were a total of 1,761,060 possible COVID-19 patients based on ICD-10 diagnostic terms and confirmatory lab results. Prior to controlling, our analysis yielded 41,608 patients who had COVID-19 resulting in two unique cohorts that were treated with either ivermectin (1,072) or remdesivir (40,536). Within the ivermectin cohort, average age was 51.9 + 17.8 years, 43% were male, 60% had glucocorticoids and 1% required ventilator support. In the remdesivir cohort, average age was 62.0 + 16.0 years, 54% were male, 64% had glucocorticoids and 2% required ventilator support. After using propensity score matching and adjusting for potential confounders, ivermectin was associated with reduced mortality vs remdesivir (OR 0.308, 95% CI (0.198,0.479)), Risk Difference -5.224%, CI (-7.079%,-3.369%), p <0.0001.

Ivermectin use was associated with decreased mortality in patients with COVID-19 compared to remdesivir. To our knowledge, this is the largest association study of patients with COVID-19, mortality and ivermectin. Further double-blinded placebo-controlled RCTs with large samples are required for definite conclusion. In the future, if more publications are published with the similar result to the current analyses, the certainty of evidence will increase.

Was published as a conference presentation

 Download the PDF from VitaminDWiki

Video review of this study by Dr. Campbell March 2022

He wondered why the results of such large studies finding such large benefits are not reported -(due to lack of money)
Low-cost Ivermectin is shunned because it results in lower income

  • Lower income to hospitals
  • Lower income to insurance companies: income is proportional to drug cost
  • Lower income to manufacturers

Similar study and results in published in Dec 2021

Ivermectin taken before COVID decreased death rate by 68 percent (3,000 with Ivermectin vs 3,000 without) - Dec 24, 2021

VitaminDWiki pages with IVERMECTIN in title (10 as of March 2022)

This list is automatically updated

Items found: 8

Created by admin. Last Modification: Saturday March 12, 2022 00:28:29 GMT-0000 by admin. (Version 7)